ClinicalTrials.gg
CompletedNCT01713530Updated Apr 2, 2018Results posted

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

A Phase 3 interventional study of insulin degludec/insulin aspart and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 51 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-02.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
42nd of 70
274 · median 384
Started
2013
with 7 others
Phase 3
49 of 70
2 open now
Registered
32nd of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 42nd largest by enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 32nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Europe and the United States of America (USA).

The aim of the trial is to compare the difference in change in glycosylated haemoglobin (HbA1c) between insulin degludec/insulin aspart (IDegAsp) and/or oral anti-diabetic drugs (OADs) and insulin degludec (IDeg) plus insulin aspart (IAsp)and/or OADs.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 274 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 Diabetes Mellitus at the discretion of the investigator for at least 26 weeks prior to screening (visit 1)
  • Treatment with basal insulin for at least 12 weeks prior to randomisation with or without metformin, sulphonylurea (SU)/glinide, DPP-4 inhibitors, alfa-glucosidase-inhibitors
  • 7.0% - 10.0%
  • (BMI) less than or equal to 40.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Treatment with glucose-lowering agent(s) other than those stated in the inclusion criteria
  • Stroke; heart failure (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
  • Chronic disorder or disease which might jeopardise safety or compliance
  • Malignant neoplasms
  • Recurrent severe hypoglycaemia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
274 participants (actual)

Study arms

  • Experimental
    IDegAsp BID+/-OADs

    Drug: insulin degludec/insulin aspart

  • Experimental
    IDeg OD plus IAsp +/-OADs

    Drug: insulin degludec · Drug: insulin aspart

Interventions

  • Druginsulin degludec/insulin aspart

    Drug pages: Insulin degludec · Insulin Aspart

    Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.

  • Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.

  • Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (%)

    Change from baseline in HbA1c (%) after 26 weeks of treatment

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline in FPG after 26 weeks of treatment

    Time frame: Week 0, week 26

  2. Number of Treatment Emergent Hypoglycaemic Episodes

    According to the Novo Nordisk definition for confirmed hypoglycaemic episodes (severe hypoglycaemia and/or a measured Plasma Glucose (PG) \<3.1 mmol/L(56 mg/dL))

    Time frame: During Weeks 0-26

  3. Number of Treatment Emergent Hypoglycaemic Episodes

    According to the American Diabetes Association (ADA) definition following are the categories of hypoglycaemic episodes: Severe hypoglycaemia, Documented symptomatic hypoglycaemia, Asymptomatic hypoglycaemia, Probable symptomatic hypoglycaemia and Relative hypoglycaemia

    Time frame: During Weeks 0-26

  4. Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes

    Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

    Time frame: Weeks 0-26

  5. Incidence of Treatment Emergent Adverse Events (TEAE)

    A TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment

    Time frame: Weeks 0-26

08

Results

Posted Nov 17, 2015

Participant flow

The trial was conducted in 5 countries (48 sites): Algeria (4), Austria (6), France (8), Norway (6) and United States (24).

Participant flow — Overall Study
MilestoneIDegAsp BIDIDeg OD+IAsp
Started138136
Exposed136135
Completed113117
Not completed2519
Withdrew: Adverse event05
Withdrew: Withdrawal criteria2112
Withdrew: Unclassified42

Outcome measures

PrimaryChange From Baseline in HbA1c (%)

Change from baseline in HbA1c (%) after 26 weeks of treatment

Time frame:
Week 0, week 26
Reported as:
Least squares mean · percentage change in HbA1c
Change From Baseline in HbA1c (%)
percentage change in HbA1cIDegAsp BIDIDeg OD+IAsp
Change From Baseline in HbA1c (%)-1.23 ± 0.13-1.42 ± 0.12
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change from baseline in FPG after 26 weeks of treatment

Time frame:
Week 0, week 26
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LIDegAsp BIDIDeg OD+IAsp
Change From Baseline in Fasting Plasma Glucose (FPG)-2.22 ± 0.38-1.90 ± 0.36
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes

According to the Novo Nordisk definition for confirmed hypoglycaemic episodes (severe hypoglycaemia and/or a measured Plasma Glucose (PG) \<3.1 mmol/L(56 mg/dL))

Time frame:
During Weeks 0-26
Reported as:
Number · episodes
Number of Treatment Emergent Hypoglycaemic Episodes
episodesIDegAsp BIDIDeg OD+IAsp
Number of Treatment Emergent Hypoglycaemic Episodes706841
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes

According to the American Diabetes Association (ADA) definition following are the categories of hypoglycaemic episodes: Severe hypoglycaemia, Documented symptomatic hypoglycaemia, Asymptomatic hypoglycaemia, Probable symptomatic hypoglycaemia and Relative hypoglycaemia

Time frame:
During Weeks 0-26
Reported as:
Number · episodes
Number of Treatment Emergent Hypoglycaemic Episodes
episodesIDegAsp BIDIDeg OD+IAsp
ADA (American Diabetes Association)28942685
Severe2915
Documented symptomatic18181843
Asymptomatic930728
Probable symptomatic2633
Relative9166
SecondaryNumber of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes

Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.

Time frame:
Weeks 0-26
Reported as:
Number · episodes
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes
episodesIDegAsp BIDIDeg OD+IAsp
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes7596
SecondaryIncidence of Treatment Emergent Adverse Events (TEAE)

A TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment

Time frame:
Weeks 0-26
Reported as:
Number · number of events
Incidence of Treatment Emergent Adverse Events (TEAE)
number of eventsIDegAsp BIDIDeg OD+IAsp
Incidence of Treatment Emergent Adverse Events (TEAE)330298

Adverse events

Collected over The adverse events (AEs) were collected for a duration of 28 weeks ie. from the first trial-related activity after the subject had signed the informed consent until the end of the post-treatment follow-up period (visit 29).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDegAsp BID—7/136 (5.1%)46/136 (33.8%)
IDeg OD+IAsp—13/135 (9.6%)38/135 (28.1%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventIDegAsp BIDIDeg OD+IAsp
Road traffic accidentInjury, poisoning and procedural complications0/1362/135
Wrong drug administeredInjury, poisoning and procedural complications0/1362/135
HypoglycaemiaMetabolism and nutrition disorders1/1362/135
Ocular hypertensionEye disorders0/1361/135
Rib fractureInjury, poisoning and procedural complications0/1361/135
Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1361/135
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1361/135
Hypoglycaemic unconsciousnessNervous system disorders1/1361/135
DepressionPsychiatric disorders0/1361/135
Suicidal ideationPsychiatric disorders0/1361/135
Most frequent other events
Most frequent other events
EventIDegAsp BIDIDeg OD+IAsp
NasopharyngitisInfections and infestations11/13612/135
AstheniaGeneral disorders10/1362/135
HeadacheNervous system disorders10/1368/135
DiarrhoeaGastrointestinal disorders9/1369/135
InfluenzaInfections and infestations9/1365/135
Pain in extremityMusculoskeletal and connective tissue disorders8/1363/135
Back painMusculoskeletal and connective tissue disorders5/1367/135
FatigueGeneral disorders7/1361/135

Baseline characteristics

The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intention-to-treat (ITT) principle and subjects contributed to the evaluation "as randomised".

Age, Continuous
Age, Continuous(years)IDegAsp BIDIDeg OD+IAspTotal
Age59.6 ± 8.359.6 ± 9.259.6 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)IDegAsp BIDIDeg OD+IAspTotal
Female6550115
Male7386159
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegAsp BIDIDeg OD+IAspTotal
Mean8.3 ± 0.98.3 ± 0.78.3 ± 0.8
Fasting plasma glucose
Fasting plasma glucose(mmol/L)IDegAsp BIDIDeg OD+IAspTotal
Mean9.0 ± 3.08.8 ± 2.98.9 ± 3.0
09

Study locations

51 sites
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    Mission Hills, California 91345, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46254, United States
  • Novo Nordisk Investigational Site
    Slidell, Louisiana 70461-4231, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Buckley, Michigan 49620, United States
  • Novo Nordisk Investigational Site
    Hillsborough, New Jersey 08844-1225, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08755-8050, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Whiteville, North Carolina 28472, United States
  • Novo Nordisk Investigational Site
    Kettering, Ohio 45429, United States
  • Novo Nordisk Investigational Site
    Wadsworth, Ohio 44281-9236, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
  • Novo Nordisk Investigational Site
    Kingsport, Tennessee 37660, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77024, United States
  • Novo Nordisk Investigational Site
    Round Rock, Texas 78681, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78224, United States
  • Novo Nordisk Investigational Site
    Tacoma, Washington 98405, United States
  • Novo Nordisk Investigational Site
    Martinsburg, West Virginia 25401, United States
  • Novo Nordisk Investigational Site
    Algiers, Algeria
  • Novo Nordisk Investigational Site
    Annaba, Algeria
  • Novo Nordisk Investigational Site
    Constantine, 25000, Algeria
  • Novo Nordisk Investigational Site
    Oran, 31000, Algeria
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Innsbruck, 6020, Austria
  • Novo Nordisk Investigational Site
    Linz, 4021, Austria
  • Novo Nordisk Investigational Site
    Mödling, 2340, Austria
  • Novo Nordisk Investigational Site
    Salzburg, 5010, Austria
  • Novo Nordisk Investigational Site
    Wien, 1090, Austria
  • Novo Nordisk Investigational Site
    Wien, 1130, Austria
  • Novo Nordisk Investigational Site
    Caen, 14033, France
  • Novo Nordisk Investigational Site
    LA ROCHE-sur-YON cedex 9, 85295, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Le Creusot, 71200, France
  • Novo Nordisk Investigational Site
    Montpellier, 34000, France
  • Novo Nordisk Investigational Site
    Montpellier, 34070, France
  • Novo Nordisk Investigational Site
    Saint Herblain, 44800, France
  • Novo Nordisk Investigational Site
    Venissieux, 69200, France
  • Novo Nordisk Investigational Site
    Hamar, 2317, Norway
  • Novo Nordisk Investigational Site
    Kongsvinger, 2212, Norway
  • Novo Nordisk Investigational Site
    Kristiansand S, 4604, Norway
  • Novo Nordisk Investigational Site
    Oslo, 0586, Norway
  • Novo Nordisk Investigational Site
    Skedsmokorset, NO-2020, Norway
  • Novo Nordisk Investigational Site
    Stavanger, 4011, Norway
10

References and documents

Publications

  • Rodbard HW, Cariou B, Pieber TR, Endahl LA, Zacho J, Cooper JG. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. Diabetes Obes Metab. 2016 Mar;18(3):274-80. doi: 10.1111/dom.12609. Epub 2016 Jan 11. PubMed 26592732 ↗
  • Haluzik M, Fulcher G, Pieber TR, Bardtrum L, Tutkunkardas D, Rodbard HW. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes. Diabetes Obes Metab. 2018 Jul;20(7):1585-1592. doi: 10.1111/dom.13261. Epub 2018 Mar 25. PubMed 29451706 ↗
  • Yang W, Akhtar S, Franek E, Haluzik M, Hirose T, Kalyanam B, Kar S, Wu T, Gogas Yavuz D, Unnikrishnan AG. Postprandial Glucose Excursions in Asian Versus Non-Asian Patients with Type 2 Diabetes: A Post Hoc Analysis of Baseline Data from Phase 3 Randomised Controlled Trials of IDegAsp. Diabetes Ther. 2022 Feb;13(2):311-323. doi: 10.1007/s13300-021-01196-7. Epub 2022 Jan 19. PubMed 35044568 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Jan 2014, 10 months.

Results were first posted in Nov 2015, 1 year 10 months after primary completion. A results delay was requested in Jan 2014.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2012
First posted
Oct 24, 2012
StartActual
Feb 21, 2013
Primary completionActual
Jan 9, 2014
CompletionActual
Jan 9, 2014
Results delay requested
Jan 24, 2014
Results first posted
Nov 17, 2015
Last update
Apr 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01713530
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 24, 2012
Start date
Feb 21, 2013
Primary completion
Jan 9, 2014
Completion
Jan 9, 2014
Results posted
Nov 17, 2015
Last update
Apr 2, 2018

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Aspart

Start the discussion